GlobeNewswire: Avinger, Inc. Contains the last 10 of 122 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T05:24:09ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/03/11/2191423/0/en/Avinger-Inc-to-Present-at-the-Q1-Virtual-Investor-Summit.html?f=22&fvtc=4&fvtv=24800Avinger, Inc. to Present at the Q1 Virtual Investor Summit2021-03-11T13:35:00Z<![CDATA[REDWOOD CITY, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire- Avinger, Inc. (Nasdaq: AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that Mark Weinswig, CFO, will be attending the Q1 Virtual Investor Summit. Management will conduct an overview presentation available on the investor relations section of Avinger’s website, www.avinger.com, and be available for one-on-one investor meetings throughout the day.]]>https://www.globenewswire.com/news-release/2019/11/05/1941601/0/en/Avinger-Reports-Third-Quarter-2019-Financial-Results.html?f=22&fvtc=4&fvtv=24800Avinger Reports Third Quarter 2019 Financial Results2019-11-05T21:01:00Z<![CDATA[Increased Utilization Drives 33% Growth in Catheter Sales and Gross Margin ExpansionTotal Pantheris Revenue Increases 81% Year-over-Year]]>https://www.globenewswire.com/news-release/2019/08/26/1906731/0/en/Avinger-Closes-4-5-Million-Equity-Offering.html?f=22&fvtc=4&fvtv=24800Avinger Closes $4.5 Million Equity Offering2019-08-26T20:02:00Z<![CDATA[REDWOOD CITY, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD) today announced the closing of an underwritten public offering of 3,813,559 shares of its common stock at a price of $1.18 per share, for total gross proceeds of approximately $4.5 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the Company has granted the underwriters a 45-day option to purchase up to 572,033 additional shares to cover over-allotments, if any. The shares were offered pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (SEC). A prospectus supplement and accompanying base prospectus relating to the offering were filed with the SEC and are available on the SEC’s website at www.sec.gov.]]>https://www.globenewswire.com/news-release/2019/08/22/1905164/0/en/Avinger-Prices-4-5-Million-Underwritten-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=24800Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock2019-08-22T01:00:00Z<![CDATA[REDWOOD CITY, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $4.5 million before deducting underwriting discounts and commissions and other estimated offering expenses. The proposed offering equates to 3,813,559 shares of the Company’s common stock at a price of $1.18 per share. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include research and development of the Company’s Lumivascular platform products, preclinical and clinical trials and studies, regulatory submissions, expansion of the Company’s sales and marketing organizations and efforts, intellectual property protection and enforcement, payment of principal and interest on debt and capital expenditures. The Company may also use a portion of the net proceeds to acquire complementary products, technologies or businesses; however, the Company currently has no agreements or commitments to complete any such transactions.]]>https://www.globenewswire.com/news-release/2019/08/21/1905108/0/en/Avinger-Announces-Proposed-Underwritten-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=24800Avinger Announces Proposed Underwritten Public Offering of Common Stock2019-08-21T20:15:00Z<![CDATA[REDWOOD CITY, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the Company expects to grant the underwriter a 45-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover over-allotments, if any. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include research and development of the Company’s Lumivascular platform products, preclinical and clinical trials and studies, regulatory submissions, expansion of the Company’s sales and marketing organizations and efforts, intellectual property protection and enforcement, payment of principal and interest on debt and capital expenditures. The Company may also use a portion of the net proceeds to acquire complementary products, technologies or businesses; however, the Company currently has no agreements or commitments to complete any such transactions. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.]]>https://www.globenewswire.com/news-release/2019/07/31/1895082/0/en/Avinger-Reports-26-Sequential-Revenue-Growth-in-Second-Quarter-2019.html?f=22&fvtc=4&fvtv=24800Avinger Reports 26% Sequential Revenue Growth in Second Quarter 20192019-07-31T20:01:00Z<![CDATA[Revenue Growth Fuels Strong Operating MetricsPantheris SV Limited Launch at Key U.S. Sites in July]]>https://www.globenewswire.com/news-release/2019/07/29/1892829/0/en/Avinger-Announces-Pantheris-SV-Limited-Launch-and-Successful-Treatment-of-First-Patients-in-the-United-States.html?f=22&fvtc=4&fvtv=24800Avinger Announces Pantheris SV Limited Launch and Successful Treatment of First Patients in the United States2019-07-29T12:00:00Z<![CDATA[REDWOOD CITY, Calif., July 29, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that physicians in four U.S. sites have successfully treated several patients with the Pantheris SV (Small Vessel) image-guided atherectomy system. These initial cases are part of a limited launch at up to 13 leading clinical centers prior to expanding commercial distribution to additional treatment facilities in the U.S.]]>https://www.globenewswire.com/news-release/2019/07/26/1892330/0/en/Avinger-to-Announce-Second-Quarter-2019-Financial-Results-on-July-31-2019.html?f=22&fvtc=4&fvtv=24800Avinger to Announce Second Quarter 2019 Financial Results on July 31, 20192019-07-26T13:00:00Z<![CDATA[REDWOOD CITY, Calif., July 26, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that it will release its financial results for the second quarter 2019 after the close of trading on Wednesday, July 31, 2019. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.]]>https://www.globenewswire.com/news-release/2019/06/21/1872608/0/en/Avinger-to-Effect-One-for-Ten-Reverse-Stock-Split.html?f=22&fvtc=4&fvtv=24800Avinger to Effect One-for-Ten Reverse Stock Split2019-06-21T20:05:00Z<![CDATA[REDWOOD CITY, Calif., June 21, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that the Company will effect a 1-for-10 reverse stock split of the Company's common stock, which will be effective at 5:00 p.m. Eastern time on Friday, June 21, 2019. As of that date, each 10 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. A new CUSIP number of 053734604 has been assigned to the Company's common stock as a result of the reverse stock split.]]>https://www.globenewswire.com/news-release/2019/05/08/1819667/0/en/Avinger-Provides-First-Quarter-2019-Shareholder-Update.html?f=22&fvtc=4&fvtv=24800Avinger Provides First Quarter 2019 Shareholder Update2019-05-08T20:01:00Z<![CDATA[Pantheris Revenue Increases 46% over Prior Year Pantheris Revenue Increases 46% over Prior Year]]>